IL17A and myeloid sarcoma: As IL-6 facilitates the differentiation of Th17 cells, one of the major pathogenic players in MS, we also detected the expression level of IL-17A, IL-17F, and IL-22, the marker genes of Th17, and the results showed that IL-17A was significantly decreased upon BVDU treatment, but IL-17F and IL-22 were not affected (Fig. 6G).